Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an announcement.
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate for its empagliflozin tablets (10 mg) from the National Medical Products Administration. This approval marks a significant step for the company in enhancing its market presence in the pharmaceutical sector, allowing it to proceed with the production and sale of this prescription drug in accordance with pharmaceutical quality management standards.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in the People’s Republic of China. It operates within the pharmaceutical industry, focusing on the production of prescription drugs. The company is engaged in the domestic production and marketing of various pharmaceutical products, including chemical drug formulations.
YTD Price Performance: -3.27%
Average Trading Volume: 3,104,833
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$9.12B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.